Exome Asset Management is an investment fund managing more than $117 billion ran by Brianne Shergill. There are currently 53 companies in Mrs. Shergill’s portfolio. The largest investments include Eli Lilly & Co and Dr Reddys Labs Ltd, together worth $13.9 billion.
As of 7th August 2024, Exome Asset Management’s top holding is 9,700 shares of Eli Lilly & Co currently worth over $7.55 billion and making up 6.5% of the portfolio value.
In addition, the fund holds 86,000 shares of Dr Reddys Labs Ltd worth $6.31 billion.
The third-largest holding is BeiGene Ltd worth $5.76 billion and the next is Cigna worth $5.56 billion, with 15,300 shares owned.
Currently, Exome Asset Management's portfolio is worth at least $117 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Exome Asset Management office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Brianne Shergill serves as the Chief Compliance Officer at Exome Asset Management.
In the most recent 13F filing, Exome Asset Management revealed that it had opened a new position in
Avidity Biosciences and bought 135,169 shares worth $3.45 billion.
This means they effectively own approximately 0.1% of the company.
Avidity Biosciences makes up
4.5%
of the fund's Health Care sector allocation and has grown its share price by 419.7% in the past year.
The investment fund also strengthened its position in BeiGene Ltd by buying
24,000 additional shares.
This makes their stake in BeiGene Ltd total 36,800 shares worth $5.76 billion.
BeiGene Ltd dropped 8.3% in the past year.
On the other hand, there are companies that Exome Asset Management is getting rid of from its portfolio.
Exome Asset Management closed its position in Immunogen on 14th August 2024.
It sold the previously owned 186,900 shares for $5.54 billion.
Brianne Shergill also disclosed a decreased stake in Dr Reddys Labs Ltd by approximately 0.1%.
This leaves the value of the investment at $6.31 billion and 86,000 shares.
The two most similar investment funds to Exome Asset Management are Tenzing Global Management and M3 Advisory. They manage $115 billion and $115 billion respectively.
Exome Asset Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 65.9% of
the total portfolio value.
The fund focuses on investments in the United States as
60.4% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
9% of the total holdings value.
On the other hand, small-cap stocks make up only 7.5% of the portfolio.
The average market cap of the portfolio companies is close to $9.89 billion.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Eli Lilly & Co |
No change
9,700
|
$7,546,212,000 | 6.46% |
| Dr Reddys Labs Ltd |
4.44%
86,000
|
$6,308,100,000 | 5.40% |
| BeiGene Ltd |
187.50%
36,800
|
$5,755,152,000 | 4.93% |
| Cigna Group (The) |
No change
15,300
|
$5,556,807,000 | 4.76% |
| Immunogen, Inc. |
Closed
186,900
|
$5,541,585,000 | |
| Alpine Immune Sciences Inc |
32.56%
117,000
|
$4,637,880,000 | 3.97% |
| TG Therapeutics Inc |
13.28%
230,300
|
$3,502,863,000 | 3.00% |
| Avidity Biosciences, Inc. |
Opened
135,169
|
$3,449,513,000 | 2.95% |
| Corbus Pharmaceuticals Hldgs |
Opened
87,846
|
$3,447,077,000 | 2.95% |
| Dexcom Inc |
No change
24,828
|
$3,443,644,000 | 2.95% |
| Centessa Pharmaceuticals Plc |
Opened
274,900
|
$3,106,370,000 | 2.66% |
| Celldex Therapeutics Inc. |
36.12%
71,100
|
$2,984,067,000 | 2.56% |
| Geron Corp. |
45.98%
886,800
|
$2,926,440,000 | 2.51% |
| Aerovate Therapeutics Inc |
Opened
98,485
|
$2,912,201,000 | 2.49% |
| Morphosys AG |
Opened
154,800
|
$2,808,072,000 | 2.40% |
| Travere Therapeutics Inc |
331.60%
362,487
|
$2,794,775,000 | 2.39% |
| Inhibrx, Inc. |
Closed
73,158
|
$2,780,004,000 | |
| Structure Therapeutics Inc |
Closed
68,100
|
$2,775,756,000 | |
| Rocket Pharmaceuticals Inc |
Closed
91,800
|
$2,751,246,000 | |
| Krystal Biotech Inc |
Opened
14,700
|
$2,615,571,000 | 2.24% |
| Intuitive Surgical Inc |
No change
6,358
|
$2,537,414,000 | 2.17% |
| Tarsus Pharmaceuticals, Inc. |
21.45%
66,300
|
$2,410,005,000 | 2.06% |
| Legend Biotech Corp |
Closed
37,900
|
$2,280,443,000 | |
| Madrigal Pharmaceuticals Inc |
40.16%
7,900
|
$2,109,616,000 | 1.81% |
| Inozyme Pharma, Inc. |
Opened
273,413
|
$2,094,344,000 | 1.79% |
| Rhythm Pharmaceuticals Inc. |
36.84%
45,603
|
$1,975,978,000 | 1.69% |
| Biohaven Ltd |
Closed
45,467
|
$1,945,988,000 | |
| Insmed Inc |
16.59%
71,700
|
$1,945,221,000 | 1.67% |
| Elevation Oncology Inc |
Opened
369,322
|
$1,894,622,000 | 1.62% |
| Exact Sciences Corp. |
Opened
26,700
|
$1,843,902,000 | 1.58% |
| Cytokinetics Inc |
25.50%
26,008
|
$1,823,421,000 | 1.56% |
| Lantheus Holdings Inc |
Closed
29,100
|
$1,804,200,000 | |
| Regenxbio Inc |
Opened
84,470
|
$1,779,783,000 | 1.52% |
| Catalyst Pharmaceuticals Inc |
Closed
105,500
|
$1,773,455,000 | |
| Biogen Inc |
No change
8,200
|
$1,768,166,000 | 1.51% |
| Ocular Therapeutix Inc |
Opened
193,600
|
$1,761,760,000 | 1.51% |
| Agios Pharmaceuticals Inc |
Opened
59,902
|
$1,751,534,000 | 1.50% |
| Natera Inc |
No change
18,650
|
$1,705,729,000 | 1.46% |
| Penumbra Inc |
14.03%
7,353
|
$1,641,043,000 | 1.41% |
| Guardant Health Inc |
Opened
79,000
|
$1,629,770,000 | 1.40% |
| Olema Pharmaceuticals, Inc. |
Opened
143,400
|
$1,623,288,000 | 1.39% |
| Arrowhead Pharmaceuticals In |
Opened
55,700
|
$1,593,020,000 | 1.36% |
| Shattuck Labs, Inc. |
Closed
223,300
|
$1,592,129,000 | |
| Vertex Pharmaceuticals, Inc. |
Closed
3,900
|
$1,586,871,000 | |
| BridgeBio Pharma Inc |
25.04%
48,807
|
$1,509,112,000 | 1.29% |
| Terns Pharmaceuticals Inc |
Opened
227,821
|
$1,494,506,000 | 1.28% |
| Marinus Pharmaceuticals Inc |
Opened
163,100
|
$1,474,424,000 | 1.26% |
| Inari Med Inc |
Opened
30,100
|
$1,444,198,000 | 1.24% |
| Quanterix Corp |
Opened
59,650
|
$1,405,354,000 | 1.20% |
| Intra-Cellular Therapies Inc |
28.27%
20,300
|
$1,404,760,000 | 1.20% |
| Immatics N.v |
Closed
129,900
|
$1,367,847,000 | |
| Prothena Corp Plc |
Closed
36,384
|
$1,322,195,000 | |
| Shockwave Med Inc |
No change
4,000
|
$1,302,520,000 | 1.12% |
| VYNE Therapeutics Inc. |
251.76%
415,434
|
$1,275,382,000 | 1.09% |
| Taysha Gene Therapies, Inc. |
Closed
693,300
|
$1,227,141,000 | |
| Macrogenics Inc |
Closed
125,900
|
$1,211,158,000 | |
| Regulus Therapeutics Inc |
125.61%
402,504
|
$1,159,212,000 | 0.99% |
| IGM Biosciences, Inc. |
Closed
135,596
|
$1,126,803,000 | |
| Q32 Bio Inc |
Opened
65,021
|
$1,107,958,000 | 0.95% |
| Cabaletta Bio Inc |
Closed
46,700
|
$1,060,090,000 | |
| Zai Lab Ltd |
Opened
65,300
|
$1,046,106,000 | 0.90% |
| Enliven Therapeutics Inc |
Opened
57,635
|
$1,013,800,000 | 0.87% |
| Mirati Therapeutics Inc |
Closed
15,896
|
$933,890,000 | |
| Ventyx Biosciences Inc |
Opened
163,922
|
$901,571,000 | 0.77% |
| Pliant Therapeutics, Inc. |
Closed
49,580
|
$897,894,000 | |
| Ultragenyx Pharmaceutical In |
Opened
17,800
|
$831,082,000 | 0.71% |
| Sage Therapeutics Inc |
Closed
35,257
|
$764,019,000 | |
| Establishment Labs Holdings Inc |
Closed
27,600
|
$714,564,000 | |
| Sutro Biopharma Inc |
Closed
153,600
|
$658,944,000 | |
| EyePoint Pharmaceuticals Inc |
Closed
26,400
|
$610,104,000 | |
| I-Mab |
Opened
325,762
|
$605,917,000 | 0.52% |
| Moonlake Immunotherapeutics |
Closed
9,744
|
$588,440,000 | |
| Procaps Group Sa |
Closed
126,901
|
$516,487,000 | |
| Adagene Inc |
Opened
155,383
|
$435,072,000 | 0.37% |
| Apellis Pharmaceuticals Inc |
Closed
7,249
|
$433,925,000 | |
| Gracell Biotechnologies Inc. |
Closed
40,974
|
$411,379,000 | |
| Sagimet Biosciences Inc |
Opened
60,900
|
$330,078,000 | 0.28% |
| Pacific Biosciences Calif In |
No change
75,300
|
$282,375,000 | 0.24% |
| Kinnate Biopharma Inc. |
Closed
83,848
|
$198,720,000 | |
| AvroBio Inc |
Opened
61,135
|
$78,253,000 | 0.07% |
| No transactions found | |||
| Showing first 500 out of 80 holdings | |||